Mock 2's Paper D (2 Feb 2021)

"To allow candidates to test the system also close to the real examination conditions, a second mock (Mock 2) is planned for the week of 1 to 5 February 2021. The examination papers will take place during that week at the same week days and times as the real examination, see here." (see e-EQE webpage)

Today, 2 February 2021, Paper D of Mock 2 was organized, using the Wiseflow platform which will be used for the e-EQE 2021 in the week of 1-5 March 2021.

I share my comments below (clock on "Read more").

Please share your experiences with the platform, as well as any comments to the paper.

Parts and breaks

Paper D was split into three parts as in the real e-EQE (see Information): 

  • two DI-parts of 90 minutes / 25 marks each, and 
  • one DII-part of 3 hours / 50 marks. 

Each part had to be completed before the start of the next break, with the next part only becoming available after the break. Candidates were thus not free to allocate their time as they see fit across the different parts of the papers (as they were since 2013). To compensate for this restriction, the total duration of the paper was extended: for each part, an additional 20% extra time was available compared to the 5-hour length of the paper itself (Rule 26(1) IPREE). 

The scheduled breaks could be used to, e.g.,  get a coffee, tea, snack, lunch, go to the toilet or go out for a quick walk.
The scheduled breaks also allowed to empty and refresh your mind, and to forget about the parts already completed, such that you were not distracted in later parts by considering if and what you may want to change something in your answer to the earlier part(s).
The scheduled break between the two DI parts also prevented candidates to some extent from running out of time for the questions of the second DI part due to a long delay or getting stuck in a question in the first part. The additional 20% extra time in each DI part was expected to be enough to compensate for the usual fluctuation of time needed for individual questions and for the limited choice of time allocation (only within a part vs over the complete paper as in D 2013-2019).

Only during part D2, candidates were allowed to take unscheduled breaks, allowing you to go to the toilet in this longer 3-hour session. (Not during the 90-minutes DI parts). When you take an unscheduled break you must inform the invigilator via the chat function, and again when you return to your desk. You do not have to wait for authorisation from the invigilator before leaving your desk. You need leave the system/browser running. (See Requirements for the e-EQE 2021).

Printing

Candidates were allowed to print only the calendar, the questions had to be taken from the screen. 

First DI part

The first 25-mark, 90 minute DI part comprised 3 questions:

  1. The first question (10 marks) addressed where to validate in view if the client's and the competitor's business (manufacturing, selling, market situation), translations for validation (full, only claims, none; time limits not all standard), and renewal fees (to EPO or to national offices with renewal falling due shortly after grant)
  2. The second question (8 marks) compared EPC and PCT time limit for filing fee (including R.19.4 situation) and additional search fee. It tested R.126(2) EPC as well as R.80.6 PCT.
  3. The last question (7 marks) was a partial priority situation for jackets made from a polymer called PoleTex where the claimed range in the subsequent EP application (0,005-0,05 pore size) was not fully disclosed in the priority application (0,05-0,1), and where a release of a product of a 0,008 pore size occurred in the priority interval.

Second DI part

The second 25-mark, 90 minute DI part also comprised 3 questions:

  • Q.4: acts in the regional phase after supplementary EP search, when a R.70(2)/70a(2) communication was just received, and in the rest of 2021.
  • Q.5 addressed various aspects of appeal: entitlement (adversely affected), what, when, substantial procedural violation or not/ (lack of) binding nature of appeal in exam in subsequent appeal in opposition (Art.111(2) & T 167/93).
  • Q.6-a) addressed time limits for various fees (in response of 71(3), appeal, PCT on filing), their amounts (could be answered with two possible sets: syllabus 31.10.2019 and 31.10.2020) - also in view of the PCT application being filed in XML (reduction in filing fee in view of PCT SoF 4, but no reduction in transmittal fee as RFees 2(3)&(4) did not yet activate those reductions (OJ 2019, A3). In b), the date and order of the various debit orders (automatic and manual) had to be discussed.

DII part

The 50-mark, 3-hour DII part had 4 questions. The first was directed, as most often, to the situation as-is. The second and third question related to improvements of our own portfolio, also in view of a European application filed by a former advisor on subject-matter to which he was or was not fully or partially entitled. The last question related to the risk of an Indian patent application. Each question had a plurality of sub-questions, giving the candidate a clear agenda as to what to discuss.

In the last several months, a Danish, Indian and EP application were filed by three different applicants; our client intends to file a PCT application claiming priority from his Danish application with additional subject-matter. No search reports are available yet from the authorities.

Aspects to be considered when answering included:

  • first and second medical use claims, directed to various specific medical indications - novelty, scope of protection
  • non-medical use
  • product claims, process claims
  • priority: all applications were filed within the last 8 months or so, such that the territorial scope of all of them could still be extended using priority - provided the first application requirement could be fulfilled.
  • priority: same applicant
  • inventorship and/vs ownership
  • prior right effects, national applications, (potential) PCT and/or EP applications
  • confidentiality
  • conference in Davos
  • handing over of a copy of a not-yet-published patent application as part of license negotiations
  • contract assigning the world-wide right to file patent applications and the priority rights
  • evident abuse - "not adequately enumerated" (depending on the choices made in improvements, you may or may not have needed this)
  • entitlement - "Please assume that under Danish law, the right to the patent belongs to the inventor but that this right can be assigned by contract"

Way of working

I answered the questions (DI as well as DII) by first copying the complete question in my answer (and doing "remove formatting" and then reformatting it) so that I could boldface/italics/underline/highlight in the question and could see it in the same Tab as my answer. I did not use any tables.

In DII, I made my annotated timeline on paper. I also made a checklist on paper of issues I ran into when reading and which I expected to require discussion when answering. 

In DII, I abbreviated my client as JCS or simple used "client"; I abbreviated Mr. Oersted to mrOe.
I abbreviated the inventions in the same way as in the paper. I copied some longer phrases from the paper into my answer when I needed, such as the long-named effects and the content of the standard contract. I used bullets and enumeration when I referred to claims of applications. 

I use headings to structure my answer, especially in questions with multiple sub-questions and in the DII. The headings can be shown in a Table of Contents in the right panel so you can check which topics you discussed. The ToC can unfortunately not be used as a navigation pane (as in, e.g., Word or Acrobat Reader).

I answered my DI as well as DII in bullet-list form. That provides for clear overview, and also provides for a convenient font size and line spacing. You can indent at various levels - increasing indent goes smoothly using the Tab-key on your keyboard; decreasing indent by one level is done by clicking in the Bullet pictogram. Here is an example:


I am a slow typer. I would have been faster by handwriting. But when I wanted to insert a few bullets and add some more legal references, the editor was very convenient, so that the disadvantage of slow typing was partially compensated by the advantage of easy editing as well as formatting options.

After all parts were finished and the complete time for all three flows had lapsed, I could download my answers from Wiseflow (Open the respective flow; you find your answer as a pdf in the lower left box, under "1. Paper").

The epi published the paper and the model solutions on their website - here.

Please feel invited to comment

Please share your experiences with the platform, as well as any comments to the paper.

We allow you to post your comments anonymously, but it is recommended and appreciated if you identify yourself using your true name or a nick name - that makes communication much more pleasant and efficient than talking to "Anonymous 19 January 2021 22:23" and alike. 
Please refer to the "Problems with commenting" link on the top right of this blog page if you have problems with commenting (which may occur due to security settings, cookies, etc, esp when using Captcha with anonymous posts).

--
Comments added 3/2/2021:

Getting stuck after copy into grey area

At the start of the second part of DI, I ran into a problem when I copied the first part of the paper n to the editor - the copied part ended up besides the editor and it looked that I got completely stuck. But I recovered using the Undo button.
This is what happened:
First, I selected all text in the separate Tab with the pdf of the paper. 
Then, I copied that into the empty editor, but I obtained this:

I.e., the editor window was still empty, but the copied text had appeared into the lower left corner of the screen, in the grey area of the Tab around the editor.
The editor controls at the top of the editor window were out of view and out of reach, so I could not to an Undo from the editor itself... and it seemed that I got stuck.
But I could recover using the Undo button (circled arrow) of the Tab (not of the editorm, but of the Tab itself), at the top right of the Tab, immediately below the WISEflow tabname: 


That got me back to the normal layout with an empty editor. 


I then copied the same part again into the editor after first having placed a space and a newline in the editor to make sure that I knew where I was pasting to.

I am not certain about the cause. But it was my first copy into an empty editor: I may not have had my cursor (target location) in the editor itself, but in the grey area around it when I pasted the copy part. I will try in paper A whether that is indeed the cause.


Copying from the paper into the editor

As in Mock 1, the copy-past from the assignment/paper into the editor still breaks the line into short pieces. 

These are the steps I take:
1. Open the paper/assignment in a separate tab
2. Select the part you want to copy


3. Use Ctrl-C to copy it onto the clip board
4. Go to the target location in the editor
5. Use Ctrl-V to paste the selected text in the editor 
6. You then get the copied part broken into short lines:

7. Use the "Undo formatting" button at the top right of the editor to remove these line breaks. Unfortunately, also the original formatting is lost, so you get a single paragraph of text, without any line beaks, without any formatting such as indentation or enumeration.
8. So, you: you will need to insert line breaks and paragraph ends, and you will need to insert several spaces as also some words got connected to obtain the question in the same paragraphs layout etc as in the paper:

That reformatting takes a few minutes for a DI question and about 5 minutes for the DII as a whole - but it makes life more easy when working on the paper thereafter. 

I also use the reformatting step:
  • to read the question (for the first time) 
  • to highlight key phrases,
  • to reformat the question when I consider that appropriate, e.g., to make a "What has to do be done when and which fees need to be paid" as an enumerated list of 3 sub-questions:
    1. What
    2. When
    3. Which fees
so the time spend is not completely lost.

Update 3/2/21, 13:10: 
A colleague informed me that instead of Ctrl-C - Ctrl-V (resulting in the broken, short sentences), it is possible to use  Ctrl-C - Ctrl-Shift-V: the latter does not result in broken sentences but copies without formatting - the result is thus one long paragraph, i.e. all line breaks are deleted but all separations between words are maintained: effectively you did step 5-7 in one go and you can proceed with step 8.

Comments

  1. I was kicked out of the session. Now trying to get back in through the zendesk website. I'm number 109 in the queue. This is going to be fun!

    ReplyDelete
    Replies
    1. Still in the queue ! No exam for me ...:-(

      Delete
    2. I'm also in the queue since one hour

      Delete
  2. I cannot start with the exam since it is not possible to upload a photo. Every time it shows me a failure in uploading the photo. Does anyone has the same problem? I think the problem is in the firewall or antivirus. However the it department said to me that they cannot deactivate them.

    ReplyDelete
  3. I already commented on the overall Mock-2 Post:

    I had the very same problem as Matt, but just after 10 minutes. Also pushed Alt-Tab on accident (twice in below on second).

    Then I got the message: "Session has been ended administratively" - "The session has been cancelled as an unauthorized action with a mouse or touchpad (a swipe with three or four fingers) has been detected several times."

    I tried to contact the inviligator by the ZenDesk Chat - Number 85 in Queue. After waiting for 50 minutes, (being number 17 in queue) everything got white, my chat inquiry vanished and I needed to reenter the message into ZenDesk - again being number 85 in queue. Was not contacted by an inviligator until the paper finished, and was not able to work on my answer any further.

    Using Alt-Tab did have no consequences in the Mock 1, and I also find no hints that it is not allowed to push some dedicated shortcuts (I thought it is the purpose of the LockDown Browser to simply "deactivate" problematic short cuts).

    Wondering what happens if one pushes the "Windows"-Key, I tried this afterwards and it allowed me to access the computer menu. This key can be hit very easily by accident.

    Very disappointing experience ...

    ReplyDelete
    Replies
    1. Same experience here...
      I got the following answer at 11h20 :
      "Please note that the invigilators will be much more responsive in the real exam. Currently, the invigilators simply test the invigilation system and there is no guarantee that they can answer in quickly. For the real exam you have their full attention."

      Delete
    2. Same issue in Mock 2 - Part D2

      Delete
    3. Same here, Around 3pm, my session was administratively ended for the reason that the system detected some unauthorized swipes (with three or four fingers) on the mouse or touchpad. I could not login anymore. I sent a message with Zendesk to an invigilator but ended in a queue of 99 people.
      I really do not know what happened to cause the end of my session. I am not feeling comfortable anymore at all about the EQE online platform.

      Delete
  4. How do you indent at various levels, I cannot seem to find this option in the editor?

    ReplyDelete
    Replies
    1. Click your Tab key on your keyboard to increase indent levels.
      Click on the enumeration or bullet icon if you want to decrease indent level.

      Delete
  5. I just gave up. At the end, I was not able to test the system.

    Display was not ok on my screen (only displayed part of the lockedbrowser).

    Tried switching to the laptop screen and from there things got mad.

    Also experienced the "please reconnect" message with the (not so)zen helpdesk.

    That does not give you confidence for the real exam. In reality, I'm afraid.

    ReplyDelete
    Replies
    1. Thank you: disabling my laptop screen before anything solved my problem! (tested with mock 1)

      I own you one beer!

      Delete
    2. Thx for the beer! When will we drink one, and where?

      Delete
  6. Technically the Mock-2 worked for me well, except for the contact with the invigilator which took too much time. I have the gut feeling that the DII part was much more complex that the previous ones. Did you have the same feeling?

    ReplyDelete
    Replies
    1. If not more complex, much different and unexpected format. I found the sub-questions confusing. I messed it up all in the end and handed in an incoherent paper I am not very happy with. Do we know if corrections will be made available?

      Delete
    2. Likewise I had an overflow of information in D2. I did not do a hand-written timeline and this does not really work out. Priority issue in D2 was complex and confusing. also the position of the other inventor etc. All in all mixed feelings. Much different from what I expected from a D2. If you loose track during your analysis you are lost and start to scroll up and down in panik.

      I had zero technical problems so I am quite lucky I guess. My camera did not turn on during D2 though, but still could write the exam and hand in.

      Delete
    3. This D2 was in various aspects a bit different than most D2s. For example, that none of the applications were filed outside the priority period such that all application could still extent their territorial scope was quite unusual - it also led you to discuss several times what the effect would be if a PCT or EP would be filed with valid priority from IN-DS (effects DK1, EP3 if revived, Euro-PCT2 if filed, "PCT3"). However, about 1 out of 4 D2s is not "standard" and this could have been a real one.
      Even if different, if you work in a structured manner and let the structure of the questions guide you as to what to answer and to what extent, I would expect that you could score quite similar on this D2 as on a "standard one".

      Delete
    4. I struggled with the typing... I am so much faster when using handwriting (but that is not very well legible...) Loads of typing errors, "use" always typed as "sue"... I may have gotten spoiled by spell checkers and auto-correct in Word...

      Delete
    5. What did you think about the DI?

      Debit orders and partial priority are likely topics for the real exam too: bring the ADA/AAD, and check out G 1/15 or our priority questions in our D-book ("Main exam questions for paper D").
      The other topics are also regularly on the exam.

      I used a quite a bit of extra time to also address the payment of renewal fees to the national offices in Q.1-c), as I expected that the payment of the renewal fee in respect of the fifth year had to be discussed, also if it could not be paid to the EPO. I then found that Romania gives more time than the 2m of Art.141(2) EPC, and that he due date runs from the anniversary there and not from the end of the month. But that was overkill...

      Delete
    6. use = sue

      :-DD

      I am happy with the typing! And with the obligatory breaks.

      Delete
    7. DI was quite normal I would say, but I had a blackout in question 4 because I wasn´t sure what the core of the question should haven been. So I lost too much time for overthinking in this question and headed to the next questions.

      Delete
  7. Yeah I thought part 2 was much harder than usual. A lot less analysis, and a lot more questions/complex issues.
    will we be able to download our answer submissions? Seems a waste of time if we can't!

    ReplyDelete
  8. I couldn't print the calendars. Luckily, I already had the calendars.

    ReplyDelete
    Replies
    1. The Calendars were also available while doing the exam under "External resources", in both DI parts as well as in DII.

      Also, you could access the EPO legal texts via "External resources", such as the ADA/AAD in OJ 2019/Suppl 4, and RFees 2020 in OJ 2020/Suppl 3 (including PCT fees fixed by WIPO payable to the EPO as RO, ISA, SISA or IPEA)

      Delete
    2. The calendars for the real exam are already available.

      See http://eqe-deltapatents.blogspot.com/2021/02/calendars-for-eqe-2021-pre-exam-and.html.

      Delete
  9. Does anyone know if/when a mark scheme or model answer will be released? I like to mark papers while they are still fresh!

    ReplyDelete
    Replies
    1. epi published them at 16:45 on https://www.epi-learning.org/course/view.php?id=18

      The answers are complete and self-explanatory.
      The answers in the model solution are based on the legal texts on 31.10.2020 (in view of the amounts given).

      Note:
      - the XML-reductions in RFees 2, 7 and 18 are not yet applicable - see OJ 2019, A3 and RFees 2(3)&(4). So, the transmittal fee is, as also indicated in the model solution, not 0 but 135 euro.
      - there is however an XML-reduction in the international filing fee, as that is provided for in the PCT SoF itself
      - for the international filing fee, you need the correct equivalent amounts.

      Delete
  10. Likewise I had an overflow of information in D2. I did not do a hand-written timeline and this does not really work out. Priority issue in D2 was complex and confusing. also the position of the other inventor etc. All in all mixed feelings. Much different from what I expected from a D2. If you loose track during your analysis you are lost and start to scroll up and down in panik.

    ReplyDelete
    Replies
    1. I completely agree. When you see the length of the standard answer (11 pages in French, see EPI website for the answer), it is very long for a question out of 50 points.

      Delete
  11. DI answers were not available for downloading before the start of the D2 session. Let's hope that it will not be the case with the C1/C2 sessions

    ReplyDelete
    Replies
    1. I noted the same. I tried to download my DI answers in the first break and the second break, but they were not yet available then. I could download all three answers after the last part - not immediately (I was ready somewhat early), but quite shortly after 16:45, i.e. after the scheduled end of the paper.

      Delete
  12. It was not what I was expecting, but I accept that. It was much less about the prior art and more about the inventorship/ownership game. I don't think that this would have been so bad if it wouldn't have been a chemical invention with multiple types of claims from a single product. Because it was an ownership issue, there were options and interactions between you and the EP3 that were not like anything i had seen before. It's not common that both you and the "enemy" can use the same application.

    The "AS IS/WILL BE" question was nebulous because the interaction between India an DK1 and EP3 didn't exactly fit this easily in my head. But there were some things that I learned from this that I will add to the test bank.

    I don't think that it was an accident that this kind of exam was given. It is a massive jolt and a wake up call. Not all methodologies work and not all exams will look like you are expecting them to.

    1 month to go!

    ReplyDelete
  13. WTF !!!
    After exactly 1 minute I've been locked out. After that the computer was completely freezed without possibility to exit. I literally had to pull the plug because everything was blocked !!!!!! I called the EPO but no one has been able to help me.

    I did too "alt+tab" involuntarily because I'm used do hundred of time during work. But from message received it seems the system had catched something else.... like mouse click, etc...

    These are pictures of my situation:

    https://imgur.com/Ks1g6W1

    https://imgur.com/BwmBZXF

    ReplyDelete
  14. 1. Paper Dii : I hope this was not representative. It was neither here nor there, not structured, several questions overlapping. I trust the real exam will be MUCH better quality.

    2a. Technique : I got kicked out due to Alt+ Tab. Unable to connect. Unable to enter in the chat. Just a blank screen that was frozen. Rebooting did not help.
    2b. Technique : The overlay worked fine for D1. But not for D2. I only got the german version. And after a while not even that: completely distorted.

    3. I tried on purpose to "upset" the system: by making a cup of tea, turning around to read in a reference book, by bending over to read a book on my lap. I never got a warning. Turned out they did not monitor this today. SUch a pity. I really wanted to know what I would be allowed to do. Especially with paper D !

    4. For D1 there was a DII-type question (partial prioritz and ranges). It was unclear to me how much legal basis had to be mentioned here, because usually in Dii there is no legal basis required.

    Anyway, time to relax now.


    ReplyDelete
  15. The Flow freezed 30min before the end of DII (just like that, not because of a wrong key) so I lost my time till the end of exam to reboot twice (as the system freezed for a second time after the first reboot), to wait for invigilator, to download my kripted paper from the laptom to the system and to restart writing - a lot of stress and lost of precious time. But I saw how the problem can be fixed and paper saved.
    A colleague waited for 2 hours to receive a passeword from invigilator.
    With hundreds of break-ups of the system today, the D test should not be classified as succesful for EPO

    ReplyDelete
  16. No technical problem on my side, neither in all Mock 1 or Mock 2 today. It is not reassuring to read all the issues some colleagues are facing. I do wonder how EPO will solve this.
    Overall, the D paper was quite balanced, a fair D-I part and a surprising D-II which gave me a hard time because it was very open in scenarios and "guiding" questions were sometime confusing. More striking is the length of model answer provided by EPI: 8 pages full of text for a 3 hours exam - analysis included - leaves very little time for proper thinking. In such an open scenario, one needs to evaluate all options (ex. I did spend some time in evaluating correcting applicant for part B and put it in the answer).

    In all, my overall impression is that this paper reflects EPO's will that candidates are not to rely mainly on D-II to pass the paper, as used to happen in the past.

    ReplyDelete
    Replies
    1. DII was far too long and very confusing in some parts,. I think they need to change DII as it is not in the format of previous papers as the EPO said.

      Delete
  17. Is there any one who was able to come back using an invigilator password after lockout due to Alt +Tab problem ?

    Also is there any one who can hand-in using locally stored data?

    I could not do both...

    ReplyDelete
  18. I have a systematic issue with the overly windows. Always show me scrambled text. The windows actually shows me the page I want to see + part of the same page in a bigger font flipped upside down on top of it. So not very helpful ....
    Further today in the DII, when opening the questions in a separate tab I was unable to scroll to the end of the last page, so i could not see the last part of question C and question D.
    And last but not least : When using Roel's Copy/paste technique from the questions/text to the answer sheet I ended up in a situation where the editor did not allow me to scroll down anymore. I could not reach lower than about 2 pages of answers. After that I was typing in the dark or had to play with the zoom (setting it to an unreadable 25pct). And even then I could not see the end as the scrolling was broken ....

    ReplyDelete
    Replies
    1. Hi gregor,

      I think I ran into the same problem at the start of the second part of DI. I have added screen shots to the blog post at the end.
      I could not scroll at all and all editor controls were out of reach (not on the screen).
      I could recover using the Undo button (circled arrow) at the top right of the screen. That got me back to the normal layout with an empty editor. I then received it into the editor after first having placed a space and a newline in the editor to make sure that I knew where I was pasting to.

      I am not certain about the cause. But it was my first copy into an empty editor: I may not have had my cursor (target location) in the editor itself, but in the grey area around it when I pasted the copy part. I will try in paper A whether that is indeed the cause.

      I had no other unexpected problems with copying. Unfortunately, the copy-past from the assignment/paper into the editor still breaks the line into short pieces, but that was expected from Mock 1. If you thereafter select the copied text and do "Undo formatting" in the top right, you get it all as one single paragraph without any line beaks, without any formatting: you will need to insert line breaks and paragraph ends, and you will need to insert several spaces as also some words got connected. That reformatting takes a few minutes for a DI question and about 5 minutes for the DII as a whole - but it makes life more easy when working on the paper thereafter. I also use the reformatting to read the question (for the first time) and to highlight key phrases, so the time spend is not completely lost.

      Delete
    2. Thanks Roel!
      Let's see how it works today!

      Delete
    3. Hi gregor,

      You can test it in Mock 1 - those flows are available until 28 February (provided you did not hand-in your answer).

      And... do not forget to do your final test in Mock 3 on 23 February!

      (http://eqe-deltapatents.blogspot.com/2021/02/e-eqe-2021-mock-3-on-23-february.html)

      Delete
  19. DII was very bizarre and the questions ended up confusing me rather than helping me.
    There were so many open ended questions and you can easily go down the wrong path/open up many rabbit holes.

    I hope DII mock 2 is not the new normal because i found it very confusing and bizarre.

    ReplyDelete
  20. timing is also very tight for paper D so they need to adjust the timings.

    ReplyDelete
  21. the EPO system today was an absolute shambles.

    ReplyDelete
  22. Hi,

    For me the e-exam worked well, however, the copy+paste function still doesn´t work very well; while pasting the text most of the words are pasted together, even after "remove formatting". Does any have any comments/suggestions regarding this issue?

    ReplyDelete
    Replies
    1. See above in my comment "Roel van Woudenberg 3 February 2021 at 08:52" in respinse to "gregor 2 February 2021 at 20:40"

      Delete
  23. 45 minutes was much too short for the lunch break.

    Can it be 1 hour 30 min please for D?

    And also for C, where we also need time in our lunch break to download our answer to part 1 and print that answer and the printable parts for part 2?

    Now let’s get ready for A, and a late lunch (without limits).

    ReplyDelete
    Replies
    1. Note that the new "Step by step to the e-EQE" document (on the e-EQE webpages - https://www.epo.org/learning/eqe/e-eqe.html) provides under item 18:

      "Printable documents will be available about 20 minutes before the start of the respective flow (a browser refresh may be required)."



      Delete
  24. I was kicked out of Wiseflow during the exam, 10mins before the end of the exam. I do not understand why, because I have a stable internet connection and everything was working fine. I also had only one tab open, so I followed all the instructions for a stable LockDown browser environment.

    By the time I reached the invigilator in the chat, due to the wait time, the exam was over and I could not hand in. So I would not have gotten any points for this exam.

    The LockDown browser has major flaws in the system. I do not know how the EPO would handle my case if it were to be the real exam. Would the last copy of my answers be corrected or would nothing be corrected as I could not hand in?

    ReplyDelete
  25. The system is not robust enough. In part 1.1, the Lockdown browser completely froze-I had no control over the mouse and couldn't do anything. I physically had to force a restart by powering off my laptop. Then the wait to get an invigilator password (112 in queue).
    I asked about extra time in the chat box -my question went unanswered -it is still unclear what would happen in the real exam. In the end of DII, I could not hand in.

    It is very worrying that a very brief power outage or break in the internet connection can cause such chaos. Similarly, an unallowable swipe of the mouse pad with 3 fingers (or it seems from above comments some key combinations) can also get you thrown out for "illegal activity". Not fit for purpose.

    ReplyDelete
  26. re DI question 1 b): In case of Romania, it overlooked that 3 june 2021 the EPO MUnchen is closed. Am I correct?

    ReplyDelete
    Replies
    1. About the shift of 3 June 2021 and EPO office closed:

      I also have the mistake in my answer. the period is not shifted due to R. 134(1) EPC because the translation must be filed at the Romanian patent office - so it does not matter that EPO is actually closed. (I guess this is the reason)

      Delete
    2. There is an argument that R. 134(1) EPC would apply because Art. 65 sets the minimum three-month period for providing the translation, which is thus a period set by the EPC. Even though the translation is not being filed at the EPO, it would still seem logical for the deadline to take into account all of the provisions of the EPC re time limits, in addition to any further provisions available under national law.
      Roel et al - can we get DeltaPatents' take on this please?

      Delete
    3. You can argue that 134(1) applies to the 3m, as that is specified in the EPC.
      It feels however awkward, as the aim of R.134 is to provide for situations where a document needs to be filed with the EPO - 134(3) only explicitly extends this to national office closures for Art.75 (filing an EP, so the time limit is typically the priority period). Nevertheless, R.134(1) does not include the limitation that the acts need to be performed with the EPO, so it seems that it applies.

      But in my view it does not apply where the national law provides a different (longer) time limit. I would indicate "R.134(1) mutatis mutandis" or "the national equivalent of R.134(1)" in my answer, or no legal basis at all (as it is not needed to give legal basis from national law).

      Delete
  27. I'm not able to access to http://epi-learning.org/. Is http://epi-learning.org/ down?

    ReplyDelete
  28. Following Article 4 of the Decision of the Supervisory Board dated 20 April 2020 and the Notice from the Examination Board of the European Qualifying Examination (EQE) dated 10 June 2020, I planned to answer the DI questions with the legal texts and document versions in force on 31 October 2019.

    However, the legal texts available in the Wiseflow Lockdown browser via “External resources” does not provide for the legal texts and document versions in force on 31 October 2019: the Guidelines are only available in HTML in the version in force on 31 October 2019 as only the November 2019 version is available. Also Rules relating to Fees on the Legal text pages (https://www.epo.org//law-practice/legal-texts/html/epc/2020/e/ma6.html) is only available in the version as last amended by decision of the Administrative Council of 27 March 2020 (the version in force as of 1 April 2020). EPC Rules were also only available in the version of today and not on the version of 31 October 2019. I could also not use the EPC from the Archive, because that is only available as a large pdf and could not be opened in the exam.

    Will I have access to both 31 October 2019 as well as 31 October 2020 legal texts in paper D on 2 March 2021?

    ReplyDelete
    Replies
    1. If only one version of Guidelines would be available, it will be the November 2019 version and not the version of 1 March 2021 that has just been announced in OJ EPO 2021, A6 and that will enter into force on 1 March 2021 and that will be published as a complete March 2021 edition that will supersede the November 2019 edition and will thus have replaced the version on the EPO website?

      Delete
    2. The epi Model Solution and Compendium-type Report for Paper DI only presents an answer based on the legal texts and document versions in force on 31 October 2020, not also an answer based on the legal texts and document versions in force on 31 October 2019.

      Delete
    3. In the webinar of 12.02.2021, it was indicated that you will (most likely) get access to the Guidelines as in force on the date of the exam, so the Guidelines of 1 March 2021. And that answers based on those would be accepted.

      But make sure to not mix Guidelines 1/3/2021 with legal texts of 31.10.2019, e.g., do not mix GL (2021) A-X, 6.2.2 and the former 10-day fail safe of RFees 7(3)/(4) for replenishing deposit accounts: the 10-day aspect of RFees 7(3) has been deleted from RFees since 01.04.2020!

      Delete
  29. re DII - I supposed that Mr. O would be fully cooperative and made an transfer of EP3 under Art. 71 EPC, then filing a PCT application in the name of Dr.s with DK2 and EP3 as valid priority claims - any comments to this?
    For uncooperative Mr. O, I supposed that EP3 is deemed withdrawn, Mr. O has no money to further process. EP3 would thus not be published and be lost. I filed a PCT application covering EP3 and DK1 in the name of Dr. S, to secure the rights to Dr. S (also to secure the rights to patent protection to both inventions,), Parts relating to MR. O could be deleted later (MR O also has to prove at court that he would be the owner of the additional inventions, since the contract might give room for interpretation; or an agreement could be reached later) effective filing date of matter relating to EP3 would be PCT filing date, anyhow no relevant prior art available. Any comments?

    Re ADA/AAD Even when reading the valid ADA/AAD as indicated by Roel I still cannot identify what the relavant parts are because there are so many back references. Would it be possible just to have an indication which points are the most relevant ones?
    re material: I am learning with Delta materials and the Syllabus materials but I am still searching for a publication of a congruence table of PCT/EP as well as combined tables such as filing requirements, time limits, Rules, Rfees - amounts - are there any or are you compiling your own tables or how do you arrange the information? Time is very short during the exam, access to the external databases might not be possible.
    My last question, when must one pay for a licence and when is it indicated to negotiate a cross-licence?

    I've run the entire paper D mock (6h) without any technical problems. I hope EPO will offer another trial for the others who envisaged frustrating problems. Many of us are "2020 resitters", learning a second time...
    Thanks a lot to all contributing to the blog, in particular Roel.

    ReplyDelete
    Replies
    1. re statement (1): It is necessary that EP3 is transferred to Dr. S for claiming priority. Dr. S and Mr. O can file PCT application together and claiming the priority.

      re statement (2):
      The FP for EP2 is still possible.

      Delete
    2. Mock 3 will allow you to test the system again on 23 February 2021.

      There will be one flow for all main exam papers (so not one flow per paper; only one for all 4 together).
      But it will not be a new paper.

      *********************************
      Use the Mock 3 opportunity to test your setup if you had any trouble or did not participate in Mock 2!!
      *********************************

      See our other blog post:
      http://eqe-deltapatents.blogspot.com/2021/02/e-eqe-2021-mock-3-on-23-february.html

      Delete
    3. @Ella:

      For a high-level PCT_EP table, you may wish to consult:

      GL/PCT-EPO General Part, 3.1 Annex I: EPC-PCT concordance table
      at
      https://www.epo.org/law-practice/legal-texts/html/guidelinespct/e/foreword_3_1.htm

      Not at all complete, but a good start.

      When I prepared for my exam, I noted many PCT Art/Rule-numbers in my EPC Reference book. That proved useful. But it was not faster than looking up PCT Information via the Applicant's Guide as that has a great keyword index.

      Delete
    4. NB: it is more complete in the next edition of the GL/PCT-EPO of 1 March 2021. That edition is prepublised as pdf on the EPO website (here: https://www.epo.org/law-practice/legal-texts/guidelines-pct/pct-guidelines-preview.html)

      Delete
  30. Due to the LockDown browser my taskmanger is blocked and I can only shut down my laptop form the login-screen - the "start" button in Win10 does not work anymore. Any ideas how to fix this?

    ReplyDelete
    Replies
    1. If you log off completely and log back in, does that work?

      I had a similar problem yesterday after Mock A and today after Mock B with the shut down button and it said "There are currently no power options available". This fixed it for me...

      Delete
    2. I had the same problem after I had to do a hard shutdown/restart - see one of our other blog posts.

      You can get the Start Menu items back if you do not Shot Down but Sign Out - and then Sign in again. At least that worked for me.

      Delete
  31. Following Article 4 of the Decision of the Supervisory Board dated 20 April 2020 and the Notice from the Examination Board of the European Qualifying Examination (EQE) dated 10 June 2020, can we use fee amounts taken from Visser (updated to 15.11.2019) and still get full marks even if these fees have since been updated/increased? Q6 of the mock gave marks for stating fee amounts and the model solutions use the latest amounts which do not correspond to the ones in Visser 2019.

    ReplyDelete
    Replies
    1. Yes, for the main exam papers of EQE 2021, you can use the legal texts in the versions in force on 31.10.2020 OR 31.10.2019 (But the Decision from the SB is silent about the version of Visser ;) ...). But do not mix the two versions, and be consistent with the correct version of the insignificant amount (that changed a few times in the last few years) and the version of Rule 103 EPC (that also changed a few times recently).

      And for both versions, the valid version of the ADA is the ADA 2019 (entered into force 1.10..2019), NOT the ADA 2017!

      Delete
  32. I had a horrible exam too.
    Please send your frustration to the eqe secreteriat too and type your experience in an email to helpdesk@eqe.org
    They must understand what a hot mess they have created.

    ReplyDelete
  33. I have a question regarding the third question in D1. About the broadest scope, why not 0.005 and 0.01-0.05 um? the element 0.005 is also novel and inventive over the element of 0.008 from the competitor. I am a bit confused.

    ReplyDelete
    Replies
    1. It seems to novel but not inventive.

      Delete
    2. I also made a remark on the single point 0.005. I think it would indeed be novel, but not inventive over 0.008.

      Even if a technical effect could be given for this particular point 0.005 over 0.008, it would then not be unitary with the rest of the range, because the point 0.008 does not share a common general inventive concept with the range. But I guess that is too far fatched.

      It is strange the model solution is silent on this.

      Delete
    3. I agree with Amelie and Lonneke: novel but not inventive (there is no information in the question that could be used to successfully argue that 0,005 would be inventive over 0,008).

      I agree with Lonneke that you could also argue non-unity. But that would not be a bar to getting it patented: if that would be the only issue you could file a divisional for it.

      Delete
    4. Hi Roel,

      0.005 is not a suggested by the disclosure 0.008. So the objective technical problem could be the provision of an alternative.

      In case of the unity: The technical problem could also be the provision of an alternative?

      Or could the provision of an alternative be regarded as a technical effect in the sense of A82 R44.

      In practice, there are a lot of granted patents based on the provision of an alternative. Therein, also alternative subject-matters are granted.

      Delete
    5. Hi Roel,

      is the assumption correct that error margins has also to be considered in the EQE? Or are error margins only relevant for the C-Paper.

      In the question of the Mock2 - Partial priority, the error margin of lower limit 0.01 is 0.005 to 0.014, and thus the disclosure of 0.008 would be novelty destroying also for the range 0.01 to 0.05.

      Delete
    6. Hi Cornelia,

      Not all alternatives are inventive.

      That an OTP can be formulated as "providing an alternative" does not necessarily render the claim inventive- you must still consider why the known solution would not be obvious in view of the CPA and the OTP.

      See GL G-VII, 5.2:
      "In this case, the problem
      has to be reformulated as the provision of an alternative product, process
      or method. The obviousness of the claimed solution to that reformulated
      problem must then be assessed in the light of the cited prior art
      (see T 87/08)"

      and GL G-VII, 3.1(i) as well as (ii):
      "3.1 Obvious and consequently non-inventive selection among a number
      of known possibilities:
      (i) The invention consists merely in choosing from a number of equally
      likely alternatives.
      Example: The invention relates to a known chemical process in
      which it is known to supply heat electrically to the reaction mixture.
      There are a number of well-known alternative ways of so supplying
      the heat, and the invention resides merely in the choice of one
      alternative.

      (ii) The invention resides in the choice of particular dimensions,
      temperature ranges or other parameters from a limited range of
      possibilities, and it is clear that these parameters could be arrived at
      by routine trial and error or by the application of normal design
      procedures.
      Example: The invention relates to a process for carrying out a known
      reaction and is characterised by a specified rate of flow of an inert
      gas. The prescribed rates are merely those which would necessarily
      be arrived at by the skilled practitioner."

      I do not see why 0,005 would be an inventive alternative w.r.t. 0,008.

      Delete
    7. Hi Lisa,

      You overlook that 0,01-0,05 benefits from partial priority and has an effective date of 21/11/2019, so that the 0,008 product released on 10/12/10 is too late to be prior art.

      Delete
    8. By the way, the name Pore-Tex was indicated as the name of a known polymer.
      If it would have been indicated as being a trademark, a clarity objection may have been considered - see GL F-IV, 4.8 -. But note that trademarks are exceptionally allowed.

      GL F-IV, 4.8 Trade marks
      The use of trademarks and similar expressions in claims is not allowed as it
      does not guarantee that the product or feature referred to is not modified
      while maintaining its name during the term of the patent. They may be
      allowed exceptionally if their use is unavoidable and they are generally
      recognised as having a precise meaning.
      With regard to the need to acknowledge trademarks as such in the
      description, see F-II, 4.14. With regard to the effect of references to trade
      marks on sufficiency of disclosure (Art. 83), see F-III,

      Delete
    9. @Lisa: yes, your assumption is correct: in the exam you need to use all the GL tests and approaches, so also that relating to numerical accuracy. See GL G-VI, 8.1.
      But -see above- your conclusion was not correct as you did not take partial priority into account.

      Delete
    10. W.R.T. inventive step - GL G-VII, 3.1(ii)

      According to the cited paragraph in the GL, a range has been suggested, so that a skilled person could arrive at an invention simply by routine experiments. However, in the present case, 0.005 is not suggested so that a skilled person in the art could not even arrive at the invention. So the would question does not seem to play a role here.

      Also in case of GL G-VII, 3.1(i), the means were suggested so that the skilled person could and would arrive at the invention.

      If a singular value does not lie in an disclosed range, could the skilled person arrive there?


      Delete
  34. Hi Roel and team,
    Quick question on R.80.6 PCT - I assume from what I can find in the L book that you agree that epi's solution was correct and that you add the days to the end before taking account of any weekends/closed days under R.80.5 PCT, rather than extending beyond what would have been available taking R.80.5 PCT into account?

    ReplyDelete
    Replies
    1. i am also a bit confused. According to Visser, "note that the extra days should be added at the end of the period, not before the period is calculated. see 4.8 for an exception to the 7-day rule by the EPO as ISA (OJ 2012 p.10)". The solution of EPI is wrong?

      Delete
    2. The addition at the end of the due date is directly derivable from the rule 80.6 itself:

      "...document or letter was received more than seven days after the date it bears, the national Office or intergovernmental organization shall treat the period starting from the date of the document or letter as expiring later by an additional number of days which is equal to the number of days which the document or letter was received later than seven days after the date it bears."

      Delete
    3. Hi Roel and team,

      I also could see in said book that R.80.6 PCT is not an aggregated time limit according to DeltaPatents. Is this correct?

      Delete
    4. The addition of the days over 7 is certainly at the end - see the citation from Amelie above.

      Whether you need to add it to the Saturday or the Monday (the 1m extended from Saturday to Monday due to R.80.6) is as far as I am aware of not documented in an official legal text.
      We assume that it adds to the Saturday - that is also the safe approach for the client. But we are not certain, it may be it adds to the Monday...
      (But... why would you wait to the last day of the term! )

      Delete
    5. @Anonymous 6 February 2021 at 22:45:
      there is nothing on OJ 2021, page 10 that relates to the topic...

      Delete
    6. Not sure if anyone still reads this, but an answer has now come up to the above question in the form of PCT-NeWsletter 2021 number 4. THe practical advice section:
      - days are added after the period R.80.6
      - if that day falls on a day on which the office is closed: period is extended R.80.5 to the next day on which it is open.

      Delete
  35. If Mr. O is not cooperating and the entitlement of EP3 is partially, it is really possible that Dr. S claims the priority of EP3?

    Is Mr. O and Dr. S a unit after partial entitlement, and they can only claim the priority of EP3 together?

    ReplyDelete
    Replies
    1. Good question. It puzzles me exceedingly too.

      I think it is logical that you can claim priority once it is clear that you were the rightful owner, but I would not know if there is a legal basis for it. The model solution does not give one either. In fact, there is quite a lot to say against it:
      - Art.61 only states that one can "prosecute" the appl. as your own. It does not say that you are considered the applicant ab initio, or something along those lines.
      - A transfer always has to take place prior to the actual filing, even if afterwards it turns out that you should have been included as applicant (see the Crispr-case).

      I only know of one decision where partial priority was applied to a transfer (T969/14) but that was really a special case.

      Delete
    2. The case law cited it really interesting.
      But does in the present case T 969/14 applies or the all applicant approach according to T 788/05?

      In T 844/18 there distinguish between both.

      What is your opinion about that?

      Delete
    3. The problem is that the committee may open the case law book and just used T 969/14 for a question but did not consider T 788/05.

      Delete
    4. In addition, if T 969/14 applies then in case a patent application is filed with the EPO by A and B and the subject-matter is divided by a contract before or after filing, then A or B can file a subsequent application without the other one for the specific subject-matter?

      Delete
    5. Hi Lonneke,

      thank you for the references!

      Does Deltapatents use T 969/14 in the D-book Edition 2021?

      In the 2020 version it is not contained.

      Delete
    6. Warning:

      For a valid claiming of priority (full or partial), the relevant transfer of the transfer of the PRIORITY RIGHT created by the filing of the earlier application, not of the earlier application as such!

      See e.g. T 407/15, in our case law blog:
      https://dp-patentlaw.blogspot.com/2021/01/t-040715-earlier-application-was.html

      NB: T 969/14 was not (yet) in our D-book edition EQE 2021. As Lonneke said, it was a very special case. Whether including it will improve your understanding of priority, partial priority and transfer of priority or only confuse you is not so clear... EQE questions are never (never say never) based on exotic case law - they are based on established and on leading case law. We may add it in a future edition, but we may also skip it and give priority ( ;) ) to other recent decisions.
      We do have a question on T 282/12, as that is a nice example on how G 1/15 also has impact on the thinking about first application!

      Delete
    7. Also see https://dp-patentlaw.blogspot.com/2018/01/t-28212-partial-priority-and-first.html for T 282/12.

      Delete
    8. Hello Roel,

      thank you very much for the answer.

      In T 969/14 the partial priority right was transferred, and the owner of one part of the priority right is file an application claiming said priority alone. Is this correct?

      When two applicants are filing one application they can only file a subsequent application claiming the priority if they file the subsequent application together (T 788/05).

      It may be that it is not allowed since an abuse by one of the applicants may be possible. However, when the priority right of the subject-matter is assigned by contract before filing the first application (partial priority) then it would the same situation as in T 969/14. Is this correct?

      Delete
    9. Hello Roel,

      there are old D-Paper, wherein it is stated that the application was transferred before filing the subsequent application without mentioning that the priority right was transferred. If I know that the priority has to be transferred alone (and this could dependent of the national law) how should I deal with this during the examination?

      Delete
    10. Can you indicate which? I think it was indicated in the last 10 years in every DII paper where it was relevant.

      I do not consider it very likely that a new DII paper will not say so it there was a transfer and the validity of priority needs to be discussed.
      But if it happens that it is not indicated whether priority was transferred, deal with it as with any uncertainty or lack of information that you may run into (usually not because there is really something missing, but because you overlook it...):
      give your full reasoning and indicate that you do not know whether priority was validly transferred or not - and especially WHY you do not know - or that you assume that it was/was not - and why you need an assumotion and cannot use a fact from the paper-.

      But (modern) DII papers usually indicate explicitly that the application as well as the priority has been transferred in a DII.
      See e.g. DII 2017 [007]:
      "After negotiations Mr G transferred ST-EP2 to us in a
      contract dated 4 April 2016 and signed by both Mr G and STEELCO. Mr G informed us
      that he had not paid any fees for the application ST-EP2. The transfer was registered
      with the EPO and includes the transfer of the right to claim priority"

      Delete
    11. In the same Paper last sentence of the 008, it is only stated that his part of application was assigned. The transfer of the priority was not mentioned:
      "[008] In February 2017, I received an e-mail from CASITAS in which they forwarded details of international application CB-PCT and according to which CB-PCT was originally filed on 10 June 2016 in the names of Mr G and CHINABEAM and claims priority from ST-EP2. CB-PCT was filed at the EPO with the EPO as International Search Authority. CASITAS informed us that Mr G subsequently assigned his share of CB-PCT to CHINABEAM"

      Delete
    12. But was it relevant? The priority right created by CB-PCT is nowhere needed, so it as not. Or?

      Delete
    13. Hello Roel,
      you are right. I am just scared to face a situation wherein the only mentions that the application has been transferred and not the priority. Of course it could be discussed but the time is running.

      Delete
    14. Hello Roel,

      may I come back to the original question.

      If Mr. O is not cooperating and the entitlement of EP3 is partially, it is really possible that Dr. S claims the priority of EP3?

      Is Mr. O and Dr. S a unit after partial entitlement, and they can only claim the priority of EP3 together?

      Mock2 was based on DII-1994. At that time T 788/05 was not known.

      So is a partial acknowledgement of the right to grant a patent, also a partial transfer of priority like in T 969/14 as mentioned by Lonneke?

      Delete
    15. @Amelie:

      See my comment above: I think it was indicated in the last 10 years in every DII paper where it was relevant. So not really needed to be scared of the information not being there (easier said than done ;)).

      All the relevant facts will be in the paper - see also Rule 22(3) IPREE. (And in the rare and exceptional events that they are not, the Committee and the Examination Board will recognize that from the premarking and from blog posts, and they will take that into account and, e.g., accept answers based on two different understandings of the paper).

      Delete
    16. @Cornelia:

      [003] of the paper:
      "Each contract contains the stipulation that Mr Oersted assigns to me the world-wide rights for inventions made in execution of the project,
      the world-wide right to file patent applications on these inventions, and the priority rights to these applications."

      Delete
    17. Hi Roel,

      thank you for reference. Since Mr. Oersted would only partially entitled to the priority right, and according to the model solution the priority of EP3 could be claimed by Mr. Oersted if the entitlement is in time.

      Does it mean that he owns a partial right of priority so that he can claim the priority of EP3 partially?

      Is there a case law for this?

      Or can T 969/14 be applied?

      Never seen another case law for partial priority due to ownership.

      Delete
    18. Difficult to say with certainty: transfer of priority is a matter of national law, as is entitlement, and thus also the relationship between the two. The EPO/EPC just follows what national law has decided - see Art. 60, 61 and PoR.

      The EPO/EPC requires that the person that uses the priority right is the owner of it - so any transfer must have taken place before the later filing if the filing is done in a different (or less) name(s).

      Maybe the phrasing "he owns a partial priorty right" is legally not so accurate and misleading:
      G 1/15 shows that the priority right is determined by what is in the priority application.
      T 969/14 shows that if there is multiple (explicit or conceptual) subject-matter in the priority application, that these are effectively independent priority rights that can be independently transferred. The transfer agreement defines how "the priority right created by the filing of the first application as a whole" is split into two parts between the two parties. That defines the two parts explicitly.

      The term "partial priority" in G 1/15 relates to a broad claim in the later applicatipn that has only for part of it a valid prioroty, because the priority document disclosed a narrower invention. But the priority rigjt as used is a full right: it is defined by what is in the priority application.

      Delete
    19. T 969/14:

      1. Validity of the priority

      1.1 Pursuant to Article 87(1) EPC, a right of priority originates in the applicant of a first application. Therefore, in principle, the applicant has to be the same for the first application and for the subsequent application for which the right of priority is invoked. However, pursuant to Article 87(1) EPC, the right of priority may also be invoked by the "successor in title" of the person who has filed the first application. By reference to the "successor in title", it is recognised that the right of priority, being a legal right, may be transferred from the original applicant to a third person. It is generally accepted that the right of priority is transferable independently of the corresponding first application. The transfer must have occurred before the filing date of the subsequent application. This is well established jurisprudence of the Boards of Appeal (cf T 205/14 of 18 June 2015, with further references).

      1.2 The application EP 00113608.4 (D16) was filed on 27 June 2000 in the name of Chiesi Farmaceutici SpA (in the following Chiesi), and the application which became the contested patent was filed in the name of Vectura Ltd (in the following Vectura) on 17 April 2001. Thus, it needs to be decided whether or not on the date of filing of the present application Vectura owned the priority right resulting from D16. As to this regard,the appellant has submitted documents D19, D20, D22, D23 and D24 to prove the transfer of the right of priority.

      1.2.1 D19, the only assignment document filed before the opposition division, is a Confirmatory Assignment, confirming the transfer of the rights in application 3 (i.e. D16) effected by a Supplemental Agreement. From this it is not clear whether only the application or also the priority right had been transferred.

      1.2.2 The Supplemental Agreement (D22) was only filed in appeal proceedings. In point 2 of it, Chiesi assigns to Vectura its rights to the ownership of application 3 (D16), but subject to the terms of this Supplemental Agreement. In point 4 it is specified that Chiesi agrees to file one or more applications taking priority from i.a. application 3 (D16) and relating to the specific Programme 2 formulations. For this purpose, Vectura will provide to Ciesi before 1 February 2001 a formal assignment of the right to claim priority for such applications from application 3 (D16). Point 5 contains that before 17 April 2001, Vectura will continue with a separate application based around the broader claims of application 3 (D16) but not including claims directed to the specific Programme 2 formulations.

      In pursuance of this agreement, an assignment was executed on 13 April 2001 (D23), in which Vectura re-assigned to Chiesi the right to claim priority from application 3 (D16) in worldwide patent applications insofar and only insofar as said worldwide patent applications shall claim the Programme 2 formulations. From this it is clear that Vectura owned, at the date of filing of their patent application, the priority right from D16, with the exception of the priority right for the Programme 2 formulations. In Schedule 2 attached to D23, the Programme 2 formulations are identified to be formulations comprising magnesium stearate in combination with specific active agents, namely "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone". These formulations are the subject of application D14 which was filed by Chiesi, implementing the agreement with Vectura and for which Chiesi owned the priority right.

      Delete
    20. 1.2.3 In decision G 1/15 (OJ EPO 2017, 82) the Enlarged Board of Appeal has ruled that entitlement to partial priority may not be refused for a claim encompassing alternative subject-matter by virtue of one or more generic expressions or otherwise (generic "OR"-claim) provided that said alternative subject-matter has been disclosed for the first time, directly, or at least implicitly, unambiguously and in an enabling manner in the priority document. In the present case, the so called Programme 2 formulations are explicitly disclosed in D16 (e.g. in claims 8 and 12) and thus can form a basis for a partial priority right. Once it is acknowledged that partial priority rights exist, they must also be transferable separately. This, however, has consequences for the remaining priority right, because the assignor is left with a limited right. The appellant (patent proprietor) referred to decision T 15/01 (OJ EPO 2006, 153) which ruled that the same priority right may be validly claimed in more than one European patent application and that there was no exhaustion of priority rights. Therefore, he was entitled to claim priority from D16 for the whole subject matter of his broader claim. However, an applicant can only claim a right which he owns and this was not the case for the priority right concerning the Programme 2 formulations. An applicant cannot transfer a partial priority right and at the same time keep it for claiming it in a broader context.

      1.2.4 Therefore, the priority situation in the present case can be illustrated as follows:

      FORMULA/TABLE/GRAPHIC

      A is the priority right owned by Vectura and encompasses any formulations excluding the specific formulations B.

      B is the priority right owned by Chiesi and relates to the specific "Programme 2 formulations" comprising magnesium stearate in combination with specific active agents, namely "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone".

      The agreements between Chiesi and Vectura on the priority rights give therefore a respective partial priority right to each company corresponding to two alternatives clearly distinct and precisely defined.

      Delete

    21. 1.3 The subject-matter of the claims as granted, namely the main request is broader than the subject-matter covered by the priority right owned by Vectura, encompassing any formulations excluding the specific formulations B.

      The subject-matter of the claims as granted relates indeed to formulations without any restriction as to the nature of the active agents or of the excipient and additive, with a unique restriction regarding the preparation of the fraction of fine particle size, namely "a fraction of fine particle size constituted of a mixture prepared by co-micronising a physiologically acceptable excipient and an additive".

      Hence, said claimed subject-matter covers explicitly also the specific formulations defined as "Programme 2 formulations" with "a fraction of fine particle size constituted of a mixture prepared by co-micronising a physiologically acceptable excipient and an additive".

      The subject-matter of claim 1 of the claims as granted of the contested patent can thus be represented as follows:

      FORMULA/TABLE/GRAPHIC

      Wherein:

      - A is the claimed subject-matter which encompasses any formulation comprising a co-micronised physiologically acceptable excipient and an additive, including specific formulations wherein magnesium stearate has been co-micronised with the excipient, and wherein the active agent may be "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone".

      - B is the priority right owned by Chiesi and the subject-matter of the application D14 relating to the specific "Programme 2 formulations" comprising magnesium stearate in combination with specific active agents, namely "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone" and wherein magnesium stearate has been co-micronised with the excipient or not.

      It appears clear that the subject-matter of claim 1 encompasses formulations for which there is no valid priority right, shown in black:

      FORMULA/TABLE/GRAPHIC

      This subject-matter relates to specific formulations of magnesium stearate with "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone" wherein magnesium stearate has been co-micronised with the excipient.

      Consequently, the subject-matter of claim 1 as granted encompasses embodiments for which the patent proprietor did not have the priority right and for which therefore the priority is not valid.

      1.4 Hence, the priority of the contested patent is not valid as far as a combination of magnesium stearate with "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone" as active ingredient is concerned (Article 87(1) EPC).

      https://www.epo.org/law-practice/case-law-appeals/recent/t140969eu1.html
      https://www.epo.org/law-practice/case-law-appeals/pdf/t140969eu1.pdf
      Use the pdf tp also see the FORMULA/TABLE/GRAPHICs

      Delete
  36. I found D-II to be very strange compared to past D-II papers. I really hope we don't get a paper like it. It tested topics that are, in my opinion, very outside the EQE. For example, medical method claims can be included for the USA. As US attorney, this is true, but they should also note that you can claim it, but the doctors are not liable in the US. Rather, you need to sue the hospital or company for induced infringement. Also, why would they make a paper about measles, viruses, and chicken pox in the middle of a pandemic? Luckily, no EQE candidate has herpes because they have been sitting inside for the last 2 years studying for this crazy exam.

    ReplyDelete
  37. Hi Roel,

    For DII, did you copy the whole text at once?

    Do you know if there is any shortcut for mac users to paste without text formatting?

    Thanks!

    ReplyDelete
    Replies
    1. I copied page-by-page.

      On Windows you can paste without the text being cut into short sentences: using Ctrl-C & Ctrl-Shift-V

      It deletes however all line breaks. So you need to insert line breaks before every paragraph number, and you need to format the Qs at the end.

      Delete
  38. A detailed question

    I wrote: The 'Pharmaceutical composition comprising product X' is also is implicitly in IN-DG, considering product X is used for a medical condition in IN-DG and therefore the product itself is a composition suitable for a pharmaceutical, and the claim towards a pharmaceutical composition in DK1 is not novel (provided that IN-DG will serve as priority for an EP/DK or DK application)

    What would you think?

    ReplyDelete
    Replies
    1. Could you please explain shortly a product itself is a composition or why a (pharmaceutical) composition it is implicitly disclosed by IN-DG?

      Delete
    2. As I see it a product is a composition consisting of one component; the product.

      'Pharmaceutical' in the composition is a suitable for, and pharmaceutical has no well-defined meaning except for suitable to be used as a medicament (so should be non-toxic and/or providing a therapeutic effect). Considering a therapeutic effect of X is in IN-DG this latter application already discloses X as suitable for a pharmaceutical application.

      Delete
    3. Actually, I agree with your analysis Vincent: The pharmaceutical composition comprising Product X (c3 in DK1) is not novel over the disclosure in IN-DG that X is used as medicament. X is implicitly disclosed in IN-DG in the form of a pharmaceutical product.
      (otherwise you would never be able to administer it).

      See also Guidelines G-VI, 7.1.2, example 2 in the table, and the note below the table:
      "Pharmaceutical comprising substance X for topical treatment" is not novel over substance X per se, if it is in a form suitable for that use.


      Delete
  39. May I add that in the cited table also Medical use claims for compounds are shown.

    Can substance X be the same like a composition?

    Does the term composition implies something?

    A composition seems to contain at least two substances.

    ReplyDelete
    Replies
    1. It has the normal meaning ;)

      D paper usually use the wording of the law if they test something non-standard, as all candidates must be able to understand the facts based on normal university-level technical knowledge and without specific technical knowledge.

      You need to know the law and the Guidelines (and the case law), in particular you need to understand and be able to apply what is in GL G-VI, 7.1 & 7.2 (First or further medical use of known products & Second non-medical use) and their sub-paragraphs.

      Art.54(4) Paragraphs 2 and 3 shall not exclude the patentability of any ***substance or composition***, comprised in the state of the art, for use in a method referred to in Article 53(c), provided that its use for any such method is not comprised in the state of the art.

      Art.54(5) Paragraphs 2 and 3 shall also not exclude the patentability of any ***substance or composition*** referred to in paragraph 4 for any specific use in a method referred to in Article 53(c), provided that such use is not comprised in the state of the art.

      Case law clarifies that other products than ***substance or composition*** can not benefit from this purpose-limited novelty (GL G-VI, 7.1.1).
      Case law also clarifies that the ***substance or composition*** should be the active agent, and not something that just happens to be part of the medical method.

      For the latter, refer toT 1758/15 cited in GL G-VI, 7.1.1; especially the sub-reasons of 5.2, of which 5.2.6 says:

      "5.2.6 In analysing Enlarged Board of Appeal decision G 5/83, Board 3.3.04 (see T 2003/08, Reasons points 15-18) came to the conclusion that G 5/83 endorsed the interpretation of the term "substance or composition" as being "the active agent or ingredient" of the particular specific medical use (see G5/93, Reasons point 23; also point 20 refers to "the active ingredient").").
      With this interpretation in mind, Board 3.3.04 developed an approach to determine whether or not "a substance or composition" is used in a treatment (Reasons point 18), an approach which may also be helpful in the present case.
      In particular, it suggested establishing (a) the means by which the therapeutic effect is achieved and (b) whether that which achieves the therapeutic effect is a chemical entity or composition of chemical entities.

      Delete
    2. Hi Roel,

      thank you for your comprehensive response.

      According to your response, a substance is not the same as a composition as I mentioned above, is this correct?

      Delete
    3. I am not a chemist, so I rely on what the question specifies.
      The D paper will be robust for candidates not knowing certaim technical terms. The DII 2019 paper even indicated "Copper is a type of metal" and "Silica is not a metal".

      Or else, the meaning from the dictionary:
      https://www.merriam-webster.com/dictionary/composition
      https://en.wikipedia.org/wiki/Chemical_composition

      Delete
  40. Hi - can anyone help me out - does R134(5) delaying of time limits apply to priority period.

    ReplyDelete
    Replies
    1. Priority period is set in PC A.4C not in EPC; it's 12m and cannot be extended.
      The European application shall be made during a period of twelve months from the date of filing of the previous application- A.87(1)
      Look at GL.A.III.6.6 which says that Rules 133 and 134 apply to the priority period under Art. 87(1). Check also GL.A.III.6.5.2-6.5.3

      Delete
    2. R.134 EPC extensions apply to any periods, also the priority period for filing a later EP application.

      NB: for a EP application, priority is determined by the self-contained EPC priority system of Art.87-89 EPC, not by Paris Convention Art. 4.

      Delete
    3. But note that R.82 and R.82quater PCT cannot be used to excuse missing the priority period when filing a PCT application too late: the 12m length of the priority period is defined in Art.4 Paris Convention, which applies via Art. 8 PCT.

      Delete
  41. Hello,

    can Rule 82quater.1 PCT and Rule 82.1 PCT apply to the entry into the national phase pursuant to A22 or A39 PCT

    ReplyDelete
    Replies
    1. Hi, for national phase before EPO - EP entry yes.
      See AG: 5.5 Unavailability of the accepted electronic means of filing debit orders
      If a payment period expires on a day on which one of the accepted means of filing debit orders under point 5.1.2 is not available at the EPO,the payment period is extended to the first day thereafter on which all such means as are available for the type of application concerned can be accessed again. In the event of a general unavailability of electronic communication services, or if other like reasons within the meaning of Rule 134(5) EPC or Rule 82quater.1 PCT arise, payment periods are extended in accordance with these provisions.
      However R.82 and R.82quater.2 do not apply to priority period

      Delete
    2. R.82.1 PCT cannot be used for a missed priority period, as not fixed in PCT Art or Rule, but in Paris Convention - EPG (2020) 2.2.021

      Rule 82quater can NOT be used not for a missed 30m/31m national entry as those are not fixed in PCT Rules, but are fixed in PCT Art (30m) / EPC Rule (31m) - EPG (2020) 2.2.021

      Delete
  42. Hello Roel,

    Thank you very much for the answer.

    Rule 82 and thus R82.1 PCT and R82quater cannot be applied for the priority period.

    However, in EPG (2020) 2.2.021 merely R82 is mentioned in conjunction with the priority period.

    The national entry is not mentioned.

    The 30 M can be found in A22 or A39 PCT and the 31 M rule can be found in R159(1), A153 EPC. So why it is not possible to apply R82 PCT since A22 and A39 set the time limit.

    For the exam, when entering the EP-Phase R133 or R134(5) has to used?

    For the exam, when entering a national phase besides EP then using R82bis.1 oder R82 quater or do I have to look it up in the AG-national phase?

    ReplyDelete
    Replies
    1. > when entering the EP-Phase R133 or R134(5) has to used?

      In my view yes:

      the time limit is a time limit specified in the EPC (Rule 159(1)) so that EPC time limit rules apply as to time limit (esp. Rule 131(4) as well as Rule 134(1)), calculation extensions and excuses (Rule 134(2), 134(5), 133) and remedies (entry acts can be remedied with further processing), and their remedies.

      Delete
  43. Hello Roel,

    when is a PCT-Rule due?

    In the DeltaPatents D-book, it is stated that the due date e.g. for the transmittal fee is 1 month after the filing of the international patent application. Is this correct?

    ReplyDelete
    Replies
    1. In PCT, in relation to fees the term "due" seems to sometimes relate to the last day and sometimes to the period during which they fee can be paid:

      See e.g., PCT Rule 16bis.1 Invitation by the Receiving Office
      (a) Where, BY THE TIME THEY ARE DUE under Rules 14.1(c), 15.3 and 16.1(f), the receiving Office finds that no fees were paid to it, or that the amount paid to it is insufficient to cover the transmittal fee, the international filing fee and the search fee, the receiving Office shall, subject to paragraph (d), invite the applicant to pay to it the amount required to cover those fees, together with, where applicable, the late payment fee under Rule 16bis.2, within a time limit of one month from the date of the invitation.

      AG-IP 5.193-194 however rather seems to use the term for the whole time span when the fees can be validly paid :

      5.193. What happens if the fees are not paid or not paid in full? Where, WITHIN THE TIME THEY ARE DUE, the applicant has not paid any or all of the fees, the receiving Office invites the applicant to pay the missing amount, together with a late payment fee, within a time limit of one month from the date of the invitation. If the applicant pays the amount (including the late payment fee) specified in the invitation, the deficiency in payment has no consequences for the international application. The amount of the late payment fee is 50% of the missing amount or, if that 50% is less than the transmittal fee, an amount equal to the transmittal fee; but the amount of the late payment fee may not exceed the amount of 50% of the international filing fee referred to in item 1 of the Schedule of Fees, not taking into account any fee for each sheet of the international application in excess of 30 sheets (see Annex C).
      5.194. Where, within the time by which they are due, the applicant has not paid any or all of the fees, any payment relating to the missing amount must be considered to have been received within the time by which those fees are due, if the payment is received by the receiving Office before that Office sends the invitation, referred to in the preceding paragraph, to pay the missing amount.

      Delete
  44. Hello Roel;

    W.R.T Deltapatents book Question L 2-18 - Correction of priority during International Phase under R91.1 PCT:

    It is stated that R91.1 can be applied within 26 M from the earliest PD.

    Unfortunately, I could not found a explicit comment for the effect before the EPO as designated office. If the correction of priority took place after the publication of the international application without a comment in said published international application pursuant to R 91.3(f).

    So it is possible that a correction of the priority pursuant to R91.1 after the publication of international application e.g. 22M after priority date which has been accepted during the international phase can be refused before the EPO as designated or elected office?

    ReplyDelete
    Replies
    1. befofre the EPO as dO, it is no longer the PCT but the EPC provisions that apply - so, Rule 139 EPC.

      Depending on the type of correction, a correction of error in a priority claim may be easy or impossible in the EP regional phase: see the Rule 139 case law on correction of priority claims.

      Delete

Post a Comment